The European Commission has approved mirvetuximab soravtansine for select patients with pretreated folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer.
SEMI, the industry association serving the global electronics design and manufacturing supply chain, today published recommendations for the European Union to bolster its semiconductor ecosystem. The ...